Prognosis of Merkel cell carcinoma patients with autoimmune disorders, other types of immune dysfunction, or immunocompetent status: Analysis of 762 patients - 11/04/24
Key words : autoimmune disease, immunosuppression, Merkel cell carcinoma, prognosis, rheumatoid arthritis
Funding sources: Supported by P01 CA225517 (“Immunobiology and Immune Therapy for Merkel Cell Carcinoma”), P30 CA015704 (NIH/NCI Cancer Center Support), Kelsey Dickson Team Science Courage Research Award Prostate Cancer Foundation, MCC Gift Fund; K23AR079588 (National Institute for Arthritis and Musculoskeletal and Skin Diseases, NIAMS). |
|
IRB approval status: All studies were performed in accordance with the Helsinki principles and were approved by the Institutional Review Board at the Fred Hutchinson Cancer Research Center (IRB #6585). All patients included in this study provided informed consent for their clinical data to be analyzed for research purposes. |
Vol 90 - N° 5
P. 1018-1020 - mai 2024 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?